IPP Bureau
Eli Lilly announces $3.5 billion Pennsylvania manufacturing hub
By IPP Bureau - January 31, 2026
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
AstraZeneca expands obesity and diabetes pipeline with $1.2B CSPC deal
By IPP Bureau - January 31, 2026
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
Astec LifeSciences posts robust Q3 growth
By IPP Bureau - January 31, 2026
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY
By IPP Bureau - January 31, 2026
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
Aster DM Healthcare reports solid Q3 FY26 growth, combined proforma revenue up 15%
By IPP Bureau - January 31, 2026
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%
By IPP Bureau - January 30, 2026
The base Gland business posted ?11,790 million in revenue, up 16% YoY
Biocon Biologics gets credit boost from S&P, outlook stable
By IPP Bureau - January 30, 2026
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
Wanbury unveils API facility in Tanuku, targets Rs. 100 crore revenue
By IPP Bureau - January 30, 2026
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
Shilpa Medicare & mAbTree Biologics win FDA nod for rare blood cancer therapy
By IPP Bureau - January 30, 2026
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
Mabtech & Sai Life Sciences launch strategic collab to revolutionize immunology research
By IPP Bureau - January 30, 2026
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
Thyrocare posts strong Q3FY26 results: revenue up 18%, PAT soars 47%
By IPP Bureau - January 30, 2026
Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
By IPP Bureau - January 30, 2026
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
Vetter to invest €480 million in major German manufacturing expansion, eyes 2,000 jobs
By IPP Bureau - January 30, 2026
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
Moderna teams up with Recordati to commercialize rare disease therapy
By IPP Bureau - January 30, 2026
AstraZeneca pledges $15 billion investment in China through 2030
By IPP Bureau - January 30, 2026
UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."
